Rhythm Pharmaceuticals

Filter

År

Typ

Språk

Rensa

2025-07-13 00:00:00 Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

2025-07-10 12:21:38 Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock 89,04 USD | +0,04%

2025-07-09 22:16:30 Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock 89,00 USD | +36,63%

2025-07-09 14:00:00 Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity 89,00 USD | +36,63%

2025-07-08 22:01:00 Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity 65,14 USD | -1,88%

2025-06-25 14:00:00 Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 62,29 USD | -2,15%

2025-05-07 13:00:00 Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update 64,63 USD | +3,06%

2025-05-06 14:00:00 Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences 62,71 USD | -2,64%

2025-04-07 13:00:00 Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity 54,96 USD | +17,06%

2025-04-06 18:00:00 Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

2025-03-20 21:01:00 Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. 54,23 USD | -1,78%

2025-03-19 21:01:00 Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan 55,21 USD | +8,32%

2025-03-18 12:00:00 Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

2025-01-10 13:15:00 Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones 56,17 USD | -2,94%

2024-12-20 20:15:00 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old 56,12 USD | +1,15%

2024-11-18 13:00:00 Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide 58,50 USD | +4,04%

2024-11-14 00:30:00 Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology 60,07 USD | -6,23%

2024-11-13 22:01:00 Rhythm Pharmaceuticals Announces New Employment Inducement Grants 60,07 USD | -6,23%

2024-11-06 14:00:00 Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences 62,65 USD | +11,38%

2024-11-05 22:01:00 Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update 56,25 USD | +6,15%

2024-11-04 22:01:00 Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 52,99 USD | +8,12%

2024-10-24 12:00:00 Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome 49,71 USD | +1,41%

2024-10-08 22:01:00 Rhythm Pharmaceuticals Announces New Employment Inducement Grants 48,09 USD | +1,89%

2024-09-16 22:01:00 Rhythm Pharmaceuticals Announces New Employment Inducement Grants 49,52 USD | -0,20%

2024-08-26 14:02:00 Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old 50,00 USD | +8,41%

2024-08-26 14:00:00 Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September 50,00 USD | +8,41%

2024-08-13 22:01:00 Rhythm Pharmaceuticals Announces New Employment Inducement Grants 45,97 USD | +3,35%

2024-08-06 13:00:00 Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update 44,04 USD | +0,02%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Rhythm Pharmaceuticals

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden